Edition:
United Kingdom

People: Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

107.40USD
13 Sep 2019
Change (% chg)

-- (--)
Prev Close
$107.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
702,410
52-wk High
$141.81
52-wk Low
$92.57

Brennan, David 

Mr. David R. Brennan is Independent Chairman of the Board of the Alexion Pharmaceuticals, Inc, He served as Interim Chief Executive Officer of Alexion from December 11, 2016 to March 27, 2017. From 2006 to 2012, he was Chief Executive Officer and Executive Director of AstraZeneca PLC, one of the world’s largest pharmaceutical companies. Mr. Brennan worked for AstraZeneca in increasing roles of responsibility from 1992 through 2012, including as Executive Vice President of North America from 2001 to 2006, and as Senior Vice President of Commercialization and Portfolio Management from 1999 to 2001. Prior to the merger of Astra AB and Zeneca Plc, he served as Senior Vice President of Business Planning and Development of Astra Pharmaceuticals LP, the American subsidiary of Astra AB. Mr. Brennan began his career at Merck and Co. Inc., where he rose from Sales Representative in the U.S. Division to General Manager of Chibret International, a French subsidiary of Merck. He received a BA in business administration from Gettysburg College, where he is the Chairman of the Board of Trustees.

Basic Compensation

Total Annual Compensation, USD 195,000
Restricted Stock Award, USD 253,858
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 448,858

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Brennan

448,858

Ludwig Hantson

16,490,200

Paul Clancy

5,486,510

Indrani Franchini

--

Ellen Chiniara

--

Anne-Marie Law

5,296,490
As Of  31 Dec 2018